Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands for articular cartilage defects of the knee and other joints: what the published clinical evidence actually shows, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México. No prices are published online — every case is reviewed in a free medical evaluation, then quoted in writing.
Mesenchymal stem cell (MSC) therapy is an investigational, physician-led option for articular cartilage defects that may reduce pain, improve function, and — in some patients — improve cartilage quality on MRI or second-look arthroscopy. Best-quality human evidence comes from small to mid-size randomized trials such as Saw 2013 and Vega 2015, along with long-term safety data from Wakitani's series. The signal is encouraging but not definitive; published systematic reviews call for larger trials with longer follow-up. At Regeneris Therapy in Cancún, México, every case starts with a free medical evaluation; only after that do you receive a personalized written quote.
The condition
Articular cartilage is the smooth, white, load-bearing tissue that covers the ends of bones inside a joint. It distributes mechanical load, reduces friction during movement, and lacks its own blood supply — which is why, once damaged, it has very limited intrinsic capacity to heal. A 'cartilage defect' is a focal area of injured or missing cartilage on a joint surface, most commonly in the knee but also in the hip, ankle, shoulder, and elbow. Defects range from small, sharp 'chondral' lesions to deeper 'osteochondral' lesions that involve the underlying bone, and many progress over time toward osteoarthritis if left untreated.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in articular cartilage pathology is encouraging but still maturing. Most of the published literature is preclinical (cell-culture and animal models); the human studies that exist range from small case series to mid-size randomized controlled trials, and reviewers — including the field's own systematic reviewers — are explicit that larger, longer, well-controlled trials are needed before MSCs can be considered an established treatment for focal cartilage defects. The notes below summarize the strongest sources we cite and what each does and does not show. None of it guarantees an individual outcome.
A Level II randomized controlled trial of 50 patients with chondral lesions of the knee compared arthroscopic subchondral drilling followed by postoperative intra-articular injections of autologous peripheral blood stem cells plus hyaluronic acid versus hyaluronic acid alone. At follow-up, the cell-injection group showed superior cartilage repair on both MRI morphologic scoring and histology of second-look biopsies, supporting a regenerative signal when biological augmentation is added to standard marrow-stimulation surgery.
Candidacy
MSC therapy for cartilage defects is not a first-line treatment, and it is not a fit for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package. Every cartilage case starts with a structured physician evaluation and ends with a written plan and a personalized quote — so you can make an informed decision before committing.
Share your goals, recent MRI, prior imaging, surgical history (including any prior microfracture, osteochondral procedure, or chondrocyte implantation), medications, and any conditions. A Regeneris physician reviews your case — by message or video first if you are traveling from outside Cancún — and answers honestly whether MSC therapy is worth considering for your defect.
We confirm defect size, depth (ICRS grade), location, and the state of the surrounding cartilage, subchondral bone, ligaments, and joint alignment. If imaging is incomplete, we tell you what is needed before any decision is made.
If MSC therapy is appropriate, you receive a written plan describing cell source, route of administration, number of sessions, any combined orthopedic procedure, post-procedure rehabilitation, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence; we are deliberately conservative because honesty is the only defensible position in a YMYL medical field.
FAQ
The questions patients ask us most when considering MSC therapy for a cartilage defect at our clinic in Cancún, México.
The honest answer is: partially, sometimes, and not for every defect. Published clinical evidence — including the Saw 2013 randomized trial after microfracture and the Vega 2015 randomized trial in knee osteoarthritis — supports a biological signal: a subset of patients show improved cartilage repair on MRI or histology and meaningful symptom relief. But MSC therapy is not known to reliably rebuild original hyaline cartilage in every patient, and the field's own systematic reviewers (Goldberg 2017) explicitly call for larger, better-controlled trials. A Regeneris physician will tell you honestly, after evaluation, whether your specific defect is reasonable to treat this way.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for cartilage defects is investigational; outcomes vary by patient, defect characteristics, and protocol, and no individual response is guaranteed. The decision to pursue MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent MRI, and any prior surgery notes. A Regeneris physician will review your case from Cancún, México and tell you — honestly — whether MSC therapy is worth considering, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.
A randomized active-control trial assigned 30 adults with knee osteoarthritis to a single intra-articular injection of allogeneic bone-marrow MSCs or hyaluronic acid. At twelve months, MSC-treated patients showed significantly greater improvement in pain and function (VAS, Lequesne, WOMAC) and quantitative MRI evidence of cartilage quality improvement (decreased poor-quality cartilage area on T2 mapping) compared with the hyaluronic acid control. The authors and regulators still classify the indication as investigational, pending larger confirmatory trials.
A long-term safety analysis of 41 patients (45 joints) who received autologous bone-marrow MSC transplantation for cartilage repair, followed for up to 11 years and 5 months (mean 75 months). No tumours and no infections attributable to the cell therapy were observed across that follow-up window. The authors concluded that autologous BM-MSC transplantation is a safe procedure — an important reference point for any honest discussion of long-term risk in regenerative cartilage care.
A PRISMA-compliant systematic review screened 2,880 records and analyzed 252 studies (100 in-vitro, 111 animal, 31 human) of MSC use for cartilage defects across multiple cell sources and delivery routes. The authors concluded that current human evidence supports a favorable safety profile and a generally positive clinical signal, but that the field lacks adequately powered randomized trials with standardized outcome measures — a stance that should anchor any honest patient conversation about what MSC therapy for cartilage can and cannot promise.
Mechanistic context that frames the cartilage literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing their therapeutic benefit comes chiefly from secreted, paracrine factors — exosomes, growth factors, cytokines — rather than from engraftment and tissue replacement. This is the underlying mechanism most often invoked to explain why an MSC injection can reduce inflammation and support cartilage health in a joint without literally rebuilding hyaline cartilage from scratch.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational for cartilage defects, shows a clinical signal in randomized studies, and has a reassuring long-term safety record — but it remains investigational. Whether it is right for your specific defect is a medical question — confirmed only in evaluation, never assumed from a search query.
Cells used in our cartilage protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic.
Every protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México. Care is not delegated to non-physician staff, and decisions are documented in your written plan.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and rest on a single short itinerary; our team helps coordinate the medical side from your first message.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up. We reassess outcomes honestly — including the option to refer you onward if a definitive surgical procedure becomes the better answer.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in: free evaluation first, written quote only after we understand your case.
Not always — and any clinic that says otherwise is overpromising. Some defects clearly need surgery (for example, a loose osteochondral fragment locking the knee, or large full-thickness defects with significant bone involvement). In other cases — symptomatic focal Grade II-III defects in patients who have failed conservative care, or post-surgical patients looking for biological augmentation as in the Saw 2013 protocol — MSC therapy may be a reasonable adjunct or alternative to consider. The decision is medical, made after imaging and an evaluation at our clinic in Cancún, México.
For focal cartilage defects, the most studied route in the published literature is intra-articular injection — placing the cell preparation directly into the affected joint, under sterile conditions and physician supervision. Some published protocols combine the injection with a surgical procedure such as arthroscopic subchondral drilling or microfracture (as in Saw 2013), or with a scaffold to hold the cells in place. Your written plan describes exactly which route applies to you and why, with no hidden steps.
Onset is gradual, not immediate. Anti-inflammatory effects can build over several weeks; structural responses, when they occur, are typically measured over several months to a year or more — consistent with the follow-up windows reported in the published trials. We schedule structured follow-up to assess symptoms, function, and (where appropriate) imaging honestly over that window.
The strongest long-term safety reference for autologous bone-marrow MSC therapy in cartilage repair is Wakitani 2011, which followed 41 patients (45 joints) for up to 11 years and 5 months and reported no tumours or infections attributable to the cell therapy. The randomized trials by Saw 2013 and Vega 2015 also reported acceptable safety profiles. Common risks of any intra-articular injection — temporary soreness, swelling, low risk of infection — are reviewed with you in your evaluation. Patients with active malignancy, active infection, pregnancy, or uncontrolled immunosuppression are generally deferred without specialist coordination.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, then a written plan and a personalized quote that reflect your specific defect, imaging, and goals. We chose this approach because medicine is not a catalog purchase — a number on a homepage cannot fairly represent the decision you are making about your joint. Your full quote is delivered in writing after evaluation, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.